Previous studies have found that delivering TMZ in the morning yields a six-month increase in overall survival, specifically for patients diagnosed with MGMT-methylated GBM tumors, with no changes in drug safety or side effects [13, 14]. The gene discussed is MGMT; the disease is glioblastoma.